Drug Database · Clinicians

Budesonide

Brands (48) Beuden, Broncort, Budecort Respules…Show all

US brand (reference label): PULMICORT RESPULES; not a Philippine-registered brand.

Corticosteroid (Corticosteroid Hormone Receptor Agonists) US FDA class
Corticosteroid (anti-asthma); Corticosteroid (glucocorticoid); and others PH FDA category

Rx · Prescription drug57 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 33cd9834-76df-4f26-3fa2-aab6b9eee8f2, version date October 11, 2019 (PULMICORT RESPULES · AstraZeneca Pharmaceuticals LP). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE PULMICORT RESPULES ® is an inhaled corticosteroid indicated for: • Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age (1) Limitations of Use: Not indicated for the relief of acute bronchospasm (1) 1.1 Maintenance Treatment of Asthma PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Limitations of Use: • PULMICORT RESPULES is NOT indicated for the relief of acute bronchospasm.

Contraindications

4 CONTRAINDICATIONS The use of PULMICORT RESPULES is contraindicated in the following conditions: • Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. • Hypersensitivity to budesonide or any of the ingredients of PULMICORT RESPULES [see Warnings and Precautions (5.3), Description (11), Adverse Reactions (6.2)]. • Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required (4) • Hypersensitivity to any of the ingredients in PULMICORT RESPULES (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

The recommended starting dose and highest recommended dose of PULMICORT RESPULES, based on prior asthma therapy, are listed in the following table. Previous Therapy Recommended Starting Dose Highest Recommended Dose Bronchodilators alone 0.5 mg total daily dose administered either once daily or twice daily in divided doses 0.5 mg total daily dose Inhaled Corticosteroids 0.5 mg total daily dose administered either once daily or twice daily in divided doses 1 mg total daily dose Oral Corticosteroids 1 mg total daily dose administered either as 0.5 mg twice daily or 1 mg once daily 1 mg total daily dose Recommended dosing based on previous therapy (2).

Start with the lowest recommended dose:

  • Bronchodilators alone: 0.5 mg once daily or 0.25 mg twice daily
  • Inhaled corticosteroids: 0.5 mg once daily or 0.25 mg twice daily up to 0.5 mg twice daily
  • Oral corticosteroids: 0.5 mg twice daily or 1 mg once daily
  • In symptomatic children not responding to non-steroidal therapy, a starting dose of 0.25 mg once daily may be considered
  • If once-daily treatment does not provide adequate control, the total daily dose should be increased and/or administered as a divided dose. Once asthma stability is achieved, titrate the dose downwards
  • For inhalation use via compressed air driven jet nebulizers only (not for use with ultrasonic devices). Not for injection. (2.2)
2.1 Dosing Recommendations

2.1 Dosing Recommendations Dosing recommendations based on previous therapy are as follows:

  • Bronchodilators alone: 0.5 mg once daily or 0.25 mg twice daily
  • Inhaled corticosteroids: 0.5 mg once daily or 0.25 mg twice daily up to 0.5 mg twice daily
  • Oral corticosteroids: 0.5 mg twice daily or 1 mg once daily In symptomatic children not responding to non-steroidal therapy, a starting dose of 0.25 mg once daily may be considered. If once-daily treatment does not provide adequate control, the total daily dose should be increased and/or administered as a divided dose. In all patients, it is desirable to downward-titrate to the lowest effective dose once asthma stability is achieved.
2.2 Directions for Use

2.2 Directions for Use PULMICORT RESPULES should be administered via jet nebulizer connected to an air compressor with an adequate air flow, equipped with a mouthpiece or suitable face mask. Ultrasonic nebulizers are not suitable for the adequate administration of PULMICORT RESPULES and, therefore, are NOT recommended. The effects of mixing PULMICORT RESPULES with other nebulizable medications have not been adequately assessed.

PULMICORT RESPULES should be administered separately in the nebulizer [see Patient Counseling Information (17.1)]. A Pari-LC-Jet Plus Nebulizer (with face mask or mouthpiece) connected to a Pari Master compressor was used to deliver PULMICORT RESPULES to each patient in 3 U.S. controlled clinical studies. The safety and efficacy of PULMICORT RESPULES delivered by other nebulizers and compressors have not been established.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment Formal pharmacokinetic studies using PULMICORT RESPULES have not been conducted in patients with hepatic impairment. However, since budesonide is predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of budesonide in plasma. Therefore, patients with hepatic disease should be closely monitored.

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness in children six months to 12 months of age has been evaluated but not established. Safety and effectiveness in children 12 months to 8 years of age have been established [see Clinical Pharmacology (12.2), Adverse Reactions (6.1)]. A 12-week study in 141 pediatric patients 6 to 12 months of age with mild to moderate asthma or recurrent/persistent wheezing was conducted.

All patients were randomized to receive either 0.5 mg or 1 mg of PULMICORT RESPULES or placebo once daily. Adrenal-axis function was assessed with an ACTH stimulation test at the beginning and end of the study, and mean changes from baseline in this variable did not indicate adrenal suppression in patients who received PULMICORT RESPULES versus placebo.

However, on an individual basis, 7 patients in this study (6 in the PULMICORT RESPULES treatment arms and 1 in the placebo arm) experienced a shift from having a normal baseline stimulated cortisol level to having a subnormal level at Week 12 [see Clinical Pharmacology (12.2)]. Pneumonia was observed more frequently in patients treated with PULMICORT RESPULES than in patients treated with placebo, (N = 2, 1, and 0) in the PULMICORT RESPULES 0.5 mg, 1 mg, and placebo groups, respectively.

A dose dependent effect on growth was also noted in this 12-week trial. Infants in the placebo arm experienced an average growth of 3.7 cm over 12 weeks compared with 3.5 cm and 3.1 cm in the PULMICORT RESPULES 0.5 mg and 1 mg arms respectively. This corresponds to estimated mean (95% CI) reductions in 12-week growth velocity between placebo and PULMICORT RESPULES 0.5 mg of 0.2 cm (-0.6 to 1.0) and between placebo and PULMICORT RESPULES 1 mg of 0.6 cm (-0.2 to 1.4).

These findings support that the use of PULMICORT RESPULES in infants 6 to 12 months of age may result in systemic effects and are consistent with findings of growth suppression in other studies with inhaled corticosteroids. Controlled clinical studies have shown that inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients.

In these studies, the mean reduction in growth velocity was approximately one centimeter per year (range 0.3 to 1.8 cm per year) and appears to be related to dose and duration of exposure. This effect has been observed in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA)-axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA-axis function.

The long-term effects of this reduction in growth velocity associated with orally inhaled corticosteroids, including the impact on final adult height, are unknown. The potential for “catch up” growth following discontinuation of treatment with orally inhaled corticosteroids has not been adequately studied. In a study of asthmatic children 5-12 years of age, those treated with budesonide administered via a dry powder inhaler 200 mcg twice daily (n=311) had a 1.1-centimeter reduction in growth compared with those receiving placebo (n=418) at the end of one year; the difference between these two treatment groups did not increase further over three years of additional treatment.

By the end of four years, children treated with the budesonide dry powder inhaler and children treated with placebo had similar growth velocities. Conclusions drawn from this study may be confounded by the unequal use of corticosteroids in the treatment groups and inclusion of data from patients attaining puberty during the course of the study.

The growth of pediatric patients receiving inhaled corticosteroids, including PULMICORT RESPULES, should be monitored routinely (e.g., via stadiometry). The potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the risks and benefits associated with alternative therapies.

To minimize the systemic effects of inhaled corticosteroids, including PULMICORT RESPULES, each patient should be titrated to his/her lowest effective dose [see Dosage and Administration (2), Warnings and Precautions (5.8)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 215 patients in 3 clinical trials of PULMICORT RESPULES in adult patients, 65 (30%) were 65 years of age or older, while 22 (10%) were 75 years of age or older. No overall differences in safety were observed between these patients and younger patients, and other reported clinical or medical surveillance experience has not identified differences in responses between the elderly and younger patients.

Dosage forms

Philippines

  • ) suspension for nebulization: 125 mcg/mL (0.25 mg/2 mL, 250 mcg/mL (500 mcg/2 mL, 250 mcg/mL (500 mcg/mL, 250 mcg/mL(500 mcg/2 mL
  • ) nebulizing suspension: 250 mcg/mL (500 mcg/2 mL, 500 mcg/mL (1000 mcg/2 mL
  • Suspension for nebulization: 1 mg/2 mL, 250 mcg/mL
  • Metered dose inhaler: 200 mcg, 200 mcg per Actuation
  • Dry powder for inhalation: 200 mcg, 200 mcg/dose
  • ): 250 mcg/mL (500 mcg/2 mL
  • ) suspension for inhalation: 250 mcg/mL (500 mcg 2 mL
  • ) suspension nebulization: 250 mcg/mL (500 mcg/2 mL
  • Aqueous nasal spray: 64 mcg per actuation
  • Dry powder in inhalation in capsule: 200 mcg

and 8 more forms; see the products table.

Registered products in the Philippines

57 products registered with the Food and Drug Administration (FDA) Philippines list Budesonide as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Budenoside (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products57
Philippine FDA-registered products for Budesonide
Package insert
AeoranBudesonide
250 mcg/mL (500mcg/2mL) Suspension For Nebulization2mL LDPE ampoule x 5's in aluminum pouch (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
ORANGE BIOTEC INC.Importer: Suhitas Pharmaceuticals Inc.
DRP-9170-03
Nov 11, 2030
AeronideBudesonide
200mcg per actuation Suspension pressurized Metered Dose InhalerAluminum canister with metered valve x 200 actuations (Box of 1's)
Rx
Inpac Pharma Co., LtdThailand
Endure Medical, Inc.,
DR-XY47983
Apr 28, 2027
AsthmacortBudesonide
250 mcg/mL Suspension for Nebulization2 mL polypropylene nebules x 5's (Box of 10's)
Rx
Ha Noi CPC1 Pharmaceutical Joint Stock CompanyVietnam
Pharmatree Inc.Importer: AMB HK Enterprises Inc.
DRP-12976-01
Nov 18, 2027
AsthonideBudesonide
200 mcg Pressurized Metered Dose InhalerAluminum canister x 200 metered doses (Box of 1's)
Rx
Medisol Lifescience Private LimitedIndia
SRS Life Sciences Inc.
DR-XY46888
May 15, 2031
AzbunideBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2 mL Polypropylene Ampoule x 5’s in Aluminum Pouch (Box of 30's)
Rx
Althea Pharma Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-10972-02
Dec 29, 2026
BeudenBudesonide
250 mcg/mL (500 mcg/ 2mL) Suspension for NebulizationLDPE Plastic Respule x 2 mL in strip of 5's with aluminum pouch (Box of 20's)
Rx
AXA Parenterals Ltd.India
All-Bio Pharma, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-9896-02
May 6, 2031
BeudenBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2.5 mL LDPE ampoule x 5's (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
All-Bio Pharma, Inc.Importer: Hillcross Prime, Inc.
DRP-15887-03
Sep 27, 2029
BreecortBudesonide
250 mcg/ mL (500 mcg/2 mL) Suspension for NebulizationLDPE Plastic Respule x 2 mL in strip of 5's with aluminum pouch (Box of 20's)
Rx
AXA Parenterals Ltd.India
The Cathay Drug Co., Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-9896-04
May 13, 2031
BronchonideBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2 mL LDPE ampoule x 5’s in aluminum pouch (Box of 25’s)
Rx
Legency Remedies Pvt. Ltd.India
Euro-Care Products PhilippinesImporter: Suhitas Pharmaceuticals Inc.
DRP-9170-04
Aug 7, 2031
BroncortBudesonide
250 mcg / mL (500 mcg / 2 mL) Suspension for Nebulization2 mL Polypropylene Ampoule x 5's in aluminum pouch (Box of 30's) and 7's in aluminum pouch (Box of 35's)
Rx
Althea Pharma Pvt. Ltd.India
Kaufmann Pharma Inc.Importer: Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-10972-01
Dec 29, 2026
BroncortBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2 mL LDPE ampoule x 5’s in aluminum pouch (Box of 25’s)
Rx
Legency Remedies Pvt. Ltd.India
Kaufmann Pharma Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-9170-05
Jul 15, 2031
BronexBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2 mL Polypropylene Ampoule x 5’s in aluminum pouch (Box of 30's) and 7’s in aluminum pouch (Box of 35's)
Rx
Althea Pharma Pvt. Ltd.India
Euro-Med Laboratories Phil., Inc.Importer: Ollen Pharma Trading, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-10972-04
Dec 29, 2026
BruxacortBudesonide
250mcg/mL Suspension For Nebulization2 mL polypropylene nebules x 5's (Box of 10's)
Rx
Ha Noi CPC1 Pharmaceutical Joint Stock CompanyVietnam
AMB HK Enterprises Inc.
DRP-12976
Nov 18, 2027
Budaxin 200Budesonide
200 mcg Dry Powder for InhalationRound shaped PP container with white HDPE with spiral containing silica gel (Box of 30's)
Rx
Mepro Pharmaceuticals Private LimitedIndia
Importer: S.M.H.P. Marketing & Consultancy
DRP-11703
Apr 19, 2027
BudecortBudesonide
200 mcg/Dose Powder for InhalationTurbuhaler x 100 doses with secondary box
Rx
AstraZeneca ABSweden
AstraZeneca Pharmaceuticals (Phils.), Inc.
DR-XY13867
Apr 3, 2027
Budecort RespulesBudesonide
250 mcg/mL (500 mcg/2 mL) Nebulizing Suspension (Sterile)Sterile Single Dose Polyethylene Plastic Unit x 2 mL (Box of 20's)
Rx
AstraZeneca AB (PET Blow Fill Seal Facility)Sweden
AstraZeneca Pharmaceuticals (Phils.), Inc.
DRP-9930
Aug 5, 2027
Budecort RespulesBudesonide
500 mcg/mL (1000 mcg/2 mL) Nebulizing Suspension (Sterile)2 mL Sterile single-dose polyethylene ampoule x 5'S in aluminum pouch (Box of 20's)
Rx
AstraZeneca AB (PET Blow Fill Seal Facility)Sweden
AstraZeneca Pharmaceuticals (Phils.), Inc.
DRP-9932
Aug 5, 2027
BudehilBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension Nebulization2.5 mL LDPE ampoule x 5's (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
Hillcross Prime, Inc.
DRP=15887
Sep 27, 2029
Budenase 0.25Budesonide
125mcg/mL (0.25 mg/2mL) Suspension for NebulizationLDPE Plastic Respule x 2 mL in strip of 5's with aluminum pouch (Box of 30's)
Rx
Cipla Limited (Unit I)India
SMHP Pharmaceuticals Incorporated
DRP-13962
May 26, 2028
Budenase 0.5Budesonide
250 mcg/mL (500 mcg 2 mL) Suspension for InhalationSingle dose Low Density Polyethylene (LDPE) Plastic form fill seal (FFS) Respule x 2 mL (Box of 20's)
Rx
Cipla Limited (Unit I)India
SMHP Pharmaceuticals Incorporated
DRP-15779
Sep 27, 2029
BudenofalkBudesonide
3 mg Enteric-Coated Pellets in CapsuleAlu/Clear PVC/PVDC Blister Pack x 10’s (Box of 100’s)
Rx
Losan Pharma GmbHGermany
A. Menarini Philippines, Inc.Trader: Dr. Falk Pharma GmbH
DR-XY27181
Nov 7, 2031
BuderiteBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2 mL LDPE Plastic ampoule x 5’s with aluminium pouch (Box of 25’s and 35’s)
Rx
Legency Remedies Pvt. Ltd.India
Preventia Healthcare Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: N/A
DRP-9170
Sep 22, 2031
BudesimBudesonide
200 mcg (0.2% w/v) Nasal SprayHDPE snap on bottle x 15 mL with actuator and protection cap (Box of 1's)
Rx
Biodeal Pharmaceuticals Pvt.Ltd.India
Airlife International Trading Corporation
DRP-18527
Aug 12, 2031
BudesmaBudesonide
200 mcg Metered Dose InhalationAluminim canister filled with metering valve x 300 metered doses
Rx
Glenmark Pharmaceuticals Ltd.India
Glenmark Philippines, Inc.
DRP-8577
Dec 27, 2028
BudesoneBudesonide
200 mcg per Actuation Metered Dose InhalerAluminum aerosol canister containing 200 metered doses with polypropylene actuator (Box of 1's)
Rx
Midas Care Pharmaceutical Pvt. Ltd.India
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-4043-01
Oct 15, 2027
BudesureBudesonide
250mcg/mL (500mcg/2mL) Suspension For NebulizationLDPE Respule x 2 mL in Laminated Film Pouch Strip x 5's (Box of 20's)
Rx
AXA Parenterals Ltd.India
Preventia Healthcare Inc.
DRP-16544
Apr 22, 2030
BudexaBudesonide
250 mcg / mL (500 mcg/2 mL) Suspension for NebulizationLDPE Plastic Respule x 2 mL in strip of 5's with aluminum pouch (Box of 20's)
Rx
AXA Parenterals Ltd.India
Sanimed Pharmaceuticals Inc.
DRP-9896
Jun 24, 2031
BudezaBudesonide
1 mg/2 mL Suspension for Nebulization2 mL LDPE ampoule in aluminum pouch (Box of 20's)
Rx
Jewim Pharmaceutical (Shandong) Co., Ltd.China
PhilRx Pharma Inc.
DRP-17806
Mar 12, 2031
BudmedBudesonide
250 mcg/mL (500 mcg/2mL) Suspension for NebulizationLDPE Plastic Respule x 2 mL in strip of 5's with aluminum pouch (Box of 20's)
Rx
AXA Parenterals Ltd.India
Madecs Pharma CorporationImporter: Sanimed Pharmaceuticals Inc.
DRP-9896-07
Apr 27, 2031
BudmedBudesonide
250 mcg/mL (500mcg/2mL) Suspension for Nebulization2.5 mL LDPE ampoule x 5's (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
Madecs Pharma CorporationImporter: Hillcross Prime, Inc.
DRP-15887-02
Sep 27, 2029
BudorespBudesonide
250mcg/mL (500mcg/2mL) Nebulizing Suspension (Sterile)LDPE Plastic Ampoule x 2mL in Silicone Polyester Film Pouch x 5's (Box of 30's)
Rx
Legency Remedies Pvt. Ltd.India
Endure Medical, Inc.
DRP-17181
Oct 16, 2030
BumedBudesonide
200 mcg per Actuation Metered Dose InhalerAluminum aerosol canister containing 200 metered doses with polypropylene actuator (in a box)
Rx
Midas Care Pharmaceutical Pvt. Ltd.India
Medethix, IncImporter: Medethix, Inc.
DRP-4043
Oct 15, 2027
BusonalBudesonide
200 mcg Metered Dose InhalerAluminum Canister Inhaler (Box of 1's)
Rx
Heilongjiang Province Fulekang Pharmaceutical Co.,Ltd.China
AMB HK Enterprises Inc.
DRP-17029
Sep 10, 2030
CopsthaBudesonide
250 mcg / mL (500 mcg / 2 mL) Suspension for NebulizationLDPE Respule x 2mL in Laminated Film Pouch Strip x 5's (Box of 20's)
Rx
AXA Parenterals LtdIndia
Slanchi Pharma Inc.Importer: Preventia Healthcare Inc.
DRP-16544-01
Apr 22, 2030
DENECORTBudesonide
250 mcg/mL (500 mcg/2mL) Nebulizing Suspension (Sterile)LDPE Plastic Ampoule x 2 mL in Aluminium Poly Pouch x 5's (Box of 30's)
Rx
Legency Remedies Pvt. Ltd.India
Phil. Pharmawealth, Inc.Importer: Endure Medical, Inc.
DRP-17181-01
Oct 16, 2030
DenecortBudesonide
250 mcg/mL Respiratory SuspensionRespules x 2 mL Box of 20's
Rx
CIPLA LTD. (UNIT I)India
PHIL. PHARMAWEALTH, INC.
DR-XY28550
Apr 15, 2028
DinosedBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2 mL Polyethylene Respules Strips x 6's packed in Aluminium Polypouch (Box of 30's)
Rx
BML Parenteral DrugsIndia
Triple Tact Import & Export Corp.
DRP-16088
Oct 29, 2029
Duasma HFA 200Budesonide
200 mcg/dose Pressurized suspension (Metered dose Cinhaler)14mL and 17mL Plain Aerosol Can
Rx
Synmosa Biopharma Corporation (Synmosa Plant)Taiwan
Endure Medical, Inc.
DR-XY49177
Sep 30, 2029
EA BudefloBudesonide
Suspension for Nebulization 250 mcg/mL (500 mcg/2 mL)2.5 mL LDPE ampoule x 5's (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
Euroasia Pharmaceuticals, Inc.Importer: Hillcross Prime, Inc.
DRP-15887-01
Sep 27, 2029
EmsonideBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization5 mL capacity (2 mL net content) LDPE nebule (Box of 35 nebules in strips of 7's in Aluminum pouch)
Rx
Ahlcon Parenterals (India) LimitedIndia
Emhealthcare Pharma Traders Inc.Importer: I.E. Medica, Inc.
DRP-6868-04
Aug 5, 2027
MaxsunideBudesonide
250 mcg / mL (500 mcg / 2 mL) Suspension for Nebulization2.5 mL LDPE ampoule x 5's (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.Distt. Solan (H.P.) 173205 India
Sefamax Pharmaceutical Products DistributionImporter: Hillcross Prime, Inc.
DRP-15887-05
Sep 27, 2029
MaxsunideBudesonide
250 mcg / mL (500 mcg/ mL) Suspension for NebulizationLDPE Plastic Respule x 2 mL in strip of 5's with aluminum pouch (Box of 20's)
Rx
AXA Parenterals Ltd.India
Sefamax Pharmaceutical Products DistributionImporter: Sanimed Pharmaceuticals Inc.
DRP-9896-05
Apr 27, 2031
MD-SONIDEBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2 mL LDPE ampoule x 5’s in aluminium pouch (Box of 25’s)
Rx
Legency Remedies Pvt. Ltd.India
MDB Pharma TradingImporter: Suhitas Pharmaceuticals Inc.
DRP-9170-02
Jul 15, 2031
NasorideBudenosideVariant spelling
64 mcg per actuation Aqueous Nasal SprayUSP Type I Amber Glass Bottle with PE Actuator (Box of 1’s)
Rx
Jewim Pharmaceutical (Shandong) Co., Ltd.China
Global Pharmatrade
DR-XY41769
Mar 7, 2030
NebucortBudesonide
250 mcg / mL (500 mcg / 2 mL) Suspension for Nebulization2 mL Polypropylene Ampoule x 5’s in aluminum pouch (Box of 30’s and 35’s)
Rx
Althea Pharma Pvt. LtdIndia
228 Pharma TradingImporter: Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-10972-03
Dec 29, 2026
Obucort SwinghalerBudesonide
200 mcg/dose Dry Powder for Inhalation (200 Doses)Plastic Container (Swinghaler) x 200 Doses (Box of 1's)
Rx
PT. Otsuka IndonesiaIndonesia
Importer: Otsuka (Philippines) Pharmaceutical, Inc.
DR-XY34048
Jan 26, 2027
PulmopedBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2 mL LDPE ampoule x 5’s in aluminum pouch (Box of 25’s)
Rx
Legency Remedies Pvt. Ltd.India
Pediawell Pharma Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-9170-07
Jul 15, 2031
Q-DesonBudesonide
250 mcg/mL Suspension for Nebulization2 mL polypropylene nebules x 5's (Box of 10's)
Rx
Ha Noi CPC1 Pharmaceutical Joint Stock CompanyVietnam
Quad-Gen PharmaceuticalsImporter: AMB HK Enterprises Inc.
DRP-12976-2
Nov 18, 2027
Respi-SaphBudesonide
250mcg/mL(500mcg/2mL) Suspension For Nebulization2.5 mL Polypropylene Ampoule x 5's in aluminum pouch (Box of 30's) and x 7's in aluminum pouch (Box of 35's)
Rx
Althea Pharma Pvt. Ltd.India
Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-10972
Dec 29, 2026
RespiGoBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2 mL LDPE ampoule x 5’s in aluminium pouch (Box of 35’s)
Rx
Legency Remedies Pvt. Ltd.India
Applied Pharmaceutical Distribution Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-9170-08
Jul 30, 2031
RetaflowBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2 mL LDPE ampoule x 5’s in aluminum pouch (Box of 25’s)
Rx
Legency Remedies Pvt. Ltd.India
Reta DrugImporter: Suhitas Pharmaceuticals Inc.
DRP-9170-06
Jul 30, 2031
RexsonideBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for NebulizationLDPE Plastic Respule x 2 mL in strip of 5's with aluminum pouch (Box of 20's)
Rx
AXA Parenterals Ltd.India
Rexmed Pharmaceutical SalesImporter: Sanimed Pharmaceuticals Inc.
DRP-9896-01
May 13, 2031
RexsonideBudesonide
250 mcg/mL (500 mcg/2mL) Suspension for Nebulization2.5 mL LDPE ampoule x 5's (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
Rexmed Pharmaceutical SalesImporter: Hillcross Prime, Inc.
DRP-15887-04
Sep 27, 2029
ZivaraBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2 mL Polyethylene Respules Strips x 6's packed in Aluminium Polypouch (Box of 30's)
Rx
BML Parenteral DrugsIndia
Greencore Pharma, Inc.Importer: Triple Tact Import & Export Corp.
DRP-16088-01
Oct 29, 2029
ZyicsBudesonide
250 mcg/mL (500 mcg/2 mL) Suspension for Nebulization2mL LDPE ampoule x 5's in aluminum pouch (Box of 25's)
Rx
Legency Remedies Pvt. LtdIndia
Zydus Healthcare Philippines Inc.Importer: Suhitas Pharmaceuticals Inc
DRP-9170-01
Nov 11, 2030
(no brand name)Budesonide
200 mcg Dry Powder in Inhalation in CapsuleAlu/Alu Blister Pack x 8's (Box of 40's)+ 1 inhaler
Rx
Lloyd Laboratories, Inc.Philippines
—
DRP-14100
Jun 21, 2028
(no brand name)Budesonide
250 mcg/mL (500 mcg/ 2mL) Suspension for NebulizationLDPE Form Fill Seal (FFS) Respule x 2 mL in Triple Laminated Foil Pouch x 5's (Box of 20's)
Rx
Cipla Ltd. (Unit I)India
Reg-A Solutions, Inc.
DR-XY47593
Dec 9, 2026

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS PULMICORT RESPULES is available in three strengths, each containing 2 mL: 0.25 mg/2 mL, 0.5 mg/2 mL, and 1 mg/2 mL. PULMICORT RESPULES is supplied in sealed aluminum foil envelopes containing one plastic strip of five single-dose RESPULES ampules together with patient instructions for use. There are 30 RESPULES ampules in a carton. Each single-dose RESPULES ampule contains 2 mL of sterile liquid suspension. Inhalation suspension: 0.25 mg/2 mL, 0.5 mg/2 mL, 1 mg/2 mL (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • • Localized Infections: Candida albicans infection of the mouth and throat may occur. Monitor patients periodically for signs of adverse effects on the oral cavity. Advise patients to rinse the mouth following inhalation (5.1)
  • • Deterioration of Disease and Acute Asthma Episodes: Do not use for the relief of acute bronchospasm (5.2)
  • • Hypersensitivity Reactions: Anaphylaxis, rash, contact dermatitis, urticaria, angioedema, and bronchospasm have been reported with use of PULMICORT RESPULES. Discontinue PULMICORT RESPULES if such reactions occur (5.3)
  • • Immunosuppression: Potential worsening of infections (e.g., existing tuberculosis, fungal, bacterial, viral, or parasitic infection; or ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients (5.4)
  • • Transferring Patients from Systemic Corticosteroid Therapy: Risk of impaired adrenal function when transferring from oral steroids. Taper patients slowly from systemic corticosteroids if transferring to PULMICORT RESPULES (5.5)
  • • Hypercorticism and Adrenal Suppression: May occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, reduce PULMICORT RESPULES slowly (5.6)
  • • Reduction in Bone Mineral Density with Long-term Administration: Monitor patients with major …
5.1 Local Effects

5.1 Local Effects In clinical trials with PULMICORT RESPULES, localized infections with Candida albicans occurred in the mouth and pharynx in some patients. The incidences of localized infections of Candida albicans were similar between the placebo and PULMICORT RESPULES treatment groups. If these infections develop, they may require treatment with appropriate local or systemic antifungal therapy and/or discontinuance of treatment with PULMICORT RESPULES.

Patients should rinse the mouth after inhalation of PULMICORT RESPULES.

5.2 Deterioration of Disease and Acute Asthma Episodes

5.2 Deterioration of Disease and Acute Asthma Episodes PULMICORT RESPULES is not a bronchodilator and is not indicated for the rapid relief of acute bronchospasm or other acute episodes of asthma. Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT RESPULES.

During such episodes, patients may require therapy with oral corticosteroids.

5.3 Hypersensitivity Reactions Including Anaphylaxis

5.3 Hypersensitivity Reactions Including Anaphylaxis Hypersensitivity reactions including anaphylaxis, rash, contact dermatitis, urticaria, angioedema, and bronchospasm have been reported with use of PULMICORT RESPULES. Discontinue PULMICORT RESPULES if such reactions occur [see Contraindications (4)].

5.4 Immunosuppression

5.4 Immunosuppression Patients who are on drugs that suppress the immune system are more susceptible to infection than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In children or adults who have not had these diseases, or been properly immunized, particular care should be taken to avoid exposure.

How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated.

If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated (see the respective package inserts for complete VZIG and IG prescribing information). If chicken pox develops, treatment with antiviral agents may be considered. The clinical course of chicken pox or measles infection in patients on inhaled corticosteroids has not been studied.

However, a clinical study has examined the immune responsiveness of asthma patients 12 months to 8 years of age who were treated with PULMICORT RESPULES. An open-label non-randomized clinical study examined the immune responsiveness of varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with PULMICORT RESPULES 0.25 mg to 1 mg daily (n=151) or non-corticosteroid asthma therapy (n=92) (i.e., beta 2 -agonists, leukotriene receptor antagonists, cromones).

The percentage of patients developing a seroprotective antibody titer of ≥5.0 (gpELISA value) in response to the vaccination was similar in patients treated with PULMICORT RESPULES (85%) compared to patients treated with non-corticosteroid asthma therapy (90%). No patient treated with PULMICORT RESPULES developed chicken pox as a result of vaccination.

Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract, untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

5.5 Transferring Patients from Systemic Corticosteroid Therapy

5.5 Transferring Patients from Systemic Corticosteroid Therapy Particular care is needed for patients who are transferred from systemically active corticosteroids to inhaled corticosteroids because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA)-axis function.

Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA-axis suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss.

Although PULMICORT RESPULES may provide control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticosteroid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies. During periods of stress or a severe asthma attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instructions.

These patients should also be instructed to carry a medical identification card indicating that they may need supplementary systemic corticosteroids during periods of stress or a severe asthma attack. Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to PULMICORT RESPULES.

Initially, PULMICORT RESPULES should be used concurrently with the patient’s usual maintenance dose of systemic corticosteroid. After approximately one week, gradual withdrawal of the systemic corticosteroid may be initiated by reducing the daily or alternate daily dose. Further incremental reductions may be made after an interval of one or two weeks, depending on the response of the patient.

Generally, these decrements should not exceed 25% of the prednisone dose or its equivalent. A slow rate of withdrawal is strongly recommended. Lung function (FEV 1 or AM PEF), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition to monitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenal insufficiency such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.

Transfer of patients from systemic corticosteroid therapy to PULMICORT RESPULES may unmask allergic or other immunologic conditions previously suppressed by the systemic corticosteroid therapy, e.g., rhinitis, conjunctivitis, eosinophilic conditions, eczema, and arthritis [see Dosage and Administration (2)]. During withdrawal from oral corticosteroids, patients may experience symptoms of systemically active corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, depression) despite maintenance or even improvement of respiratory function.

5.6 Hypercorticism and Adrenal Suppression

5.6 Hypercorticism and Adrenal Suppression PULMICORT RESPULES, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing PULMICORT RESPULES.

Because of the possibility of systemic absorption of inhaled corticosteroids, patients treated with PULMICORT RESPULES should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients post-operatively or during periods of stress for evidence of inadequate adrenal response.

It is possible that systemic corticosteroid effects such as hypercorticism, and adrenal suppression (including adrenal crisis) may appear in a small number of patients, particularly when budesonide is administered at higher than recommended doses over prolonged periods of time. If such effects occur, the dosage of PULMICORT RESPULES should be reduced slowly, consistent with accepted procedures for tapering of systemic corticosteroids and for management of asthma.

5.7 Reduction in Bone Mineral Density

5.7 Reduction in Bone Mineral Density Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids. The clinical significance of small changes in BMD with regard to long-term outcomes is unknown. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids), should be monitored and treated with established standards of care.

5.8 Effects on Growth

5.8 Effects on Growth Orally inhaled corticosteroids, including budesonide, may cause a reduction in growth velocity when administered to pediatric patients. Monitor the growth of pediatric patients receiving PULMICORT RESPULES routinely (e.g., via stadiometry). To minimize the systemic effects of orally inhaled corticosteroids, including PULMICORT RESPULES, each patient should be titrated to his/her lowest effective dose [see Use in Specific Populations (8.4)].

5.9 Glaucoma and Cataracts

5.9 Glaucoma and Cataracts Glaucoma, increased intraocular pressure, and cataracts have been reported following the long-term administration of inhaled corticosteroids, including budesonide. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.

5.10 Paradoxical Bronchospasm and Upper Airway Symptoms

5.10 Paradoxical Bronchospasm and Upper Airway Symptoms As with other inhaled asthma medications, bronchospasm, with an immediate increase in wheezing, may occur after dosing. If acute bronchospasm occurs following dosing with PULMICORT RESPULES, it should be treated immediately with a fast-acting inhaled bronchodilator.

Treatment with PULMICORT RESPULES should be discontinued and alternate therapy instituted.

5.11 Eosinophilic Conditions and Churg-Strauss Syndrome

5.11 Eosinophilic Conditions and Churg-Strauss Syndrome In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions. Some of these patients have clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition that is often treated with systemic corticosteroids therapy.

These events usually, but not always, have been associated with the reduction and/or withdrawal of oral corticosteroid therapy following the introduction of inhaled corticosteroids. Healthcare providers should be alert to eosinophilia, vasculitis rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients.

A causal relationship between budesonide and these underlying conditions has not been established.

5.12 Drug Interactions with Strong Cytochrome P450 3

5.12 Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of PULMICORT RESPULES with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to increased systemic exposure to budesonide may occur [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Strong Cytochrome P450 3A4 Inhibitors (e.g., ritonavir): Use with caution. May cause increased systemic corticosteroid effects (5.12, 7.1) 7.1 Inhibitors of Cytochrome P450 3A4 The main route of metabolism of corticosteroids, including budesonide, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased.

Concomitant administration of a CYP3A4 inhibitor may inhibit the metabolism of, and increase the systemic exposure to, budesonide. Caution should be exercised when considering the coadministration of PULMICORT RESPULES with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions (5.12), Clinical Pharmacology (12.3)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Two major metabolites formed via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4) catalyzed biotransformation have been isolated and identified as 16α-hydroxyprednisolone and 6β-hydroxybudesonide.

Drug-Drug Interactions Inhibitors of cytochrome P450 enzymes Ketoconazole: Ketoconazole, a strong inhibitor of cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4), the main metabolic enzyme for corticosteroids, increased plasma levels of orally ingested budesonide [see Warnings and Precautions (5.12) , Drug Interactions (7.1) ] .

May cause increased systemic corticosteroid effects ( 5.12 , 7.1 ) 7.1 Inhibitors of Cytochrome P450 3A4 The main route of metabolism of corticosteroids, including budesonide, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4).

After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased.

Concomitant administration of a CYP3A4 inhibitor may inhibit the metabolism of, and increase the systemic exposure to, budesonide.

Caution should be exercised when considering the coadministration of PULMICORT RESPULES with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions (5.12) , Clinical Pharmacology (12.3) ] .

Adverse reactions

Adverse reactions (US label) US FDA label
  • Systemic and inhaled corticosteroid use may result in the following: • Candida albicans Infection [see Warnings and Precautions (5.1)] • Hypersensitivity Reactions Including Anaphylaxis [see Warnings and Precautions (5.3)] • Immunosuppression [see Warnings and Precautions (5.4)] • Hypercorticism and Adrenal Suppression [see Warnings and Precautions (5.6)] • Reduction in Bone Mineral Density [see Warnings and Precautions (5.7)] • Growth Effects in Pediatric Patients [see Warnings and Precautions (5.8), Use in Specific Populations (8.4)] • Glaucoma, Increased Intraocular Pressure and Cataracts [see Warnings and Precautions (5.9)] • Eosinophilic Conditions and Churg-Strauss Syndrome [see Warnings and Precautions (5.11)] Most common adverse reactions (incidence > 3%) are respiratory infection, rhinitis, coughing, otitis media, viral infection, moniliasis, gastroenteritis, vomiting, diarrhea, abdominal pain, ear infection, epistaxis, conjunctivitis, rash (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1–800–236–9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The incidence of common adverse reactions is based on three double-blind, placebo-controlled, randomized U.S. clinical trials in which 945 patients, 12 months to 8 years of age, (98 patients ≥12 months and <2 years of age; 225 patients ≥2 and <4 years of age; and 622 patients ≥4 and ≤8 years of age) were treated with PULMICORT RESPULES (0.25 to 1 mg total daily dose for 12 weeks) or vehicle placebo.

The incidence and nature of adverse events reported for PULMICORT RESPULES was comparable to that reported for placebo. The following table shows the incidence of adverse events in U.S. controlled clinical trials, regardless of relationship to treatment, in patients previously receiving bronchodilators and/or inhaled corticosteroids.

This population included a total of 605 male and 340 female patients and 78.4% were Caucasian, 13.8% African American, 5.5% Hispanic and 2.3% Other. Table 1 – Adverse Reactions occurring at an incidence of ≥3% in at least one active treatment group where the incidence was higher with PULMICORT RESPULES than placebo Adverse Events Vehicle Placebo (n=227) % PULMICORT RESPULES Total Daily Dose 0.25 mg (n=178) % 0.5 mg (n=223) % 1 mg (n=317) % Respiratory System Disorder Respiratory Infection 36 34 35 38 Rhinitis 9 7 11 12 Coughing 5 5 9 8 Resistance Mechanism Disorders Otitis Media 11 12 11 9 Viral Infection 3 4 5 3 Moniliasis 2 4 3 4 Gastrointestinal System Disorders Gastroenteritis 4 5 5 5 Vomiting 3 2 4 4 Diarrhea 2 4 4 2 Abdominal Pain 2 3 2 3 Hearing and Vestibular Disorders Ear Infection 4 2 4 5 Platelet, Bleeding and Clotting Disorders Epistaxis 1 2 4 3 Vision Disorders Conjunctivitis 2 <1 4 2 Skin and Appendages Disorders Rash 3 <1 4 2 The information below includes all adverse reactions by system organ class with an incidence of 1 to < 3%, in at least one PULMICORT RESPULES treatment group where the incidence was higher with PULMICORT RESPULES than with placebo, regardless of relationship to treatment.

Blood and lymphatic system disorders: cervical lymphadenopathy Ear and labyrinth disorders: earache General disorders and administration site conditions: fatigue, flu-like disorder Immune system disorders: allergic reaction Infections and infestations: eye infection, herpes simplex, external ear infection, infection Injury, poisoning and procedural complication: fracture Metabolism and nutrition disorders: anorexia Musculoskeletal and connective tissue disorders: myalgia Nervous system disorders: hyperkinesia Psychiatric disorders: emotional lability Respiratory, thoracic, and mediastinal disorders: chest pain, dysphonia, stridor Skin and subcutaneous tissue disorders: contact dermatitis, eczema, pustular rash, pruritus, purpura The incidence of reported adverse events was similar between the 447 PULMICORT RESPULES-treated (mean total daily dose 0.5 to 1 mg) and 223 conventional therapy-treated pediatric asthma patients followed for one year in three open-label studies.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been reported during post-approval use of PULMICORT RESPULES. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Some of these adverse reactions may also have been observed in clinical studies with PULMICORT RESPULES. Endocrine disorders: symptoms of hypocorticism and hypercorticism [see Warnings and Precautions (5.6)] Eye disorders: cataracts, glaucoma, increased intraocular pressure [see Warnings and Precautions (5.9)] General disorders and administration site conditions: fever, pain Immune system disorders: immediate and delayed hypersensitivity reactions including, anaphylaxis, angioedema, bronchospasm, rash, contact dermatitis, and urticaria [see Contraindications (4), Warnings and Precautions (5.10)] Infection and Infestation: sinusitis, pharyngitis, bronchitis Musculoskeletal and connective tissue disorders: avascular necrosis of the femoral head, osteoporosis, growth suppression Nervous system disorders: headache Psychiatric disorders: psychiatric symptoms including psychosis, depression, aggressive reactions, irritability, nervousness, restlessness, and anxiety Respiratory, thoracic, and mediastinal disorders: cough, dysphonia and throat irritation Skin and subcutaneous tissue disorders: skin bruising, facial skin irritation Cases of growth suppression have been reported for inhaled corticosteroids including post-marketing reports for PULMICORT RESPULES [see Warnings and Precautions (5.8), Use in Specific Populations (8.4)].

Adverse reaction frequency tables (US label) US FDA label
Table 1 – Adverse Reactions occurring at an incidence of ≥3% in at least one active treatment group where the incidence was higher with PULMICORT RESPULES than placebo
Adverse EventsVehicle Placebo(n=227)%PULMICORT RESPULESTotal Daily Dose
0.25 mg(n=178)%0.5 mg(n=223)%1 mg(n=317)%
Respiratory System Disorder
Respiratory Infection36343538
Rhinitis971112
Coughing5598
Resistance Mechanism Disorders
Otitis Media1112119
Viral Infection3453
Moniliasis2434
Gastrointestinal System Disorders
Gastroenteritis4555
Vomiting3244
Diarrhea2442
Abdominal Pain2323
Hearing and Vestibular Disorders
Ear Infection4245
Platelet, Bleeding and Clotting Disorders
Epistaxis1243
Vision Disorders
Conjunctivitis2<142
Skin and Appendages Disorders
Rash3<142

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no adequate well-controlled studies of PULMICORT RESPULES in pregnant women. However, there are published studies on the use of budesonide, the active ingredient in PULMICORT RESPULES, in pregnant women. In animal reproduction studies, budesonide, administered by the subcutaneous route, caused structural abnormalities, was embryocidal, and reduced fetal weights in rats and rabbits at less than the maximum recommended human daily inhalation dose (MRHDID), but these effects were not seen in rats that received inhaled doses approximately 2 times the MRHDID (see Data).

Studies of pregnant women have not shown that inhaled budesonide increases the risk of abnormalities when administered during pregnancy. Experience with oral corticosteroids suggests that rodents are more prone to structural abnormalities from corticosteroid exposure than humans. The estimated background risk of major birth defects and miscarriage of the indicated populations is unknown.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal risk In women with poorly or moderately controlled asthma, there is an increased risk of several perinatal adverse outcomes such as preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate.

Pregnant women with asthma should be closely monitored and medication adjusted as necessary to maintain optimal asthma control. Labor or Delivery There are no well-controlled human studies that have investigated the effects of PULMICORT RESPULES during labor and delivery. Data Human Data Studies of pregnant women have not shown that inhaled budesonide increases the risk of abnormalities when administered during pregnancy.

The results from a large population-based prospective cohort epidemiological study reviewing data from three Swedish registries covering approximately 99% of the pregnancies from 1995-1997 (i.e., Swedish Medical Birth Registry; Registry of Congenital Malformations; Child Cardiology Registry) indicate no increased risk for congenital malformations from the use of inhaled budesonide during early pregnancy. Congenital malformations were studied in 2014 infants born to mothers reporting the use of inhaled budesonide for asthma in early pregnancy (usually 10-12 weeks after the last menstrual period), the period when most major organ malformations occur.

The rate of recorded congenital malformations was similar compared to the general population rate (3.8% vs. 3.5%, respectively). In addition, after exposure to inhaled budesonide, the number of infants born with orofacial clefts was similar to the expected number in the normal population (4 children vs. 3.3, respectively).

These same data were utilized in a second study bringing the total to 2534 infants whose mothers were exposed to inhaled budesonide. In this study, the rate of congenital malformations among infants whose mothers were exposed to inhaled budesonide during early pregnancy was not different from the rate for all newborn babies during the same period (3.6%).

Animal Data In a fertility and reproduction study, male rats were subcutaneously dosed for 9 weeks and females for 2 weeks prior to pairing and throughout the mating period. Females were dosed up until weaning of their offspring. Budesonide caused a decrease in prenatal viability and viability in the pups at birth and during lactation, along with a decrease in maternal body-weight gain, at doses 0.2 times the MRHDID (on a mcg/m 2 basis at maternal subcutaneous doses of 20 mcg/kg/day and above).

No such effects were noted at a dose 0.05 times the MRHDID (on a mcg/m 2 basis at a maternal subcutaneous dose of 5 mcg/kg/day). In an embryo-fetal development study in pregnant rabbits dosed during the period of organogenesis from gestation days 6-18, budesonide produced fetal loss, decreased fetal weight, and skeletal abnormalities at doses 0.5 times the MRHDID (on a mcg/m 2 basis at a maternal subcutaneous dose of 25 mcg/kg/day).

In an embryo-fetal development study in pregnant rats dosed during the period of organogenesis from gestation days 6-15, budesonide produced similar adverse fetal effects at doses approximately 5 times the MRHDID (on a mcg/m 2 basis at a maternal subcutaneous dose of 500 mcg/kg/day). In another embryo-fetal development study in pregnant rats, no structural abnormalities or embryocidal effects were seen at doses approximately 2 times the MRHDID (on a mcg/m 2 basis at maternal inhalation doses up to 250 mcg/kg/day).

In a peri-and post-natal development study, rats dosed from gestation day 15 to postpartum day 21, budesonide had no effects on delivery, but did have an effect on growth and development of offspring. Offspring survival was reduced and surviving offspring had decreased mean body weights at birth and during lactation at doses less than 0.2 times the MRHDID and higher (on a mcg/m 2 basis at maternal subcutaneous doses of 20 mcg/kg/day and higher).

These findings occurred in the presence of maternal toxicity.

Mechanism of action

12.1 Mechanism of Action Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. In standard in vitro and animal models, budesonide has approximately a 200-fold higher affinity for the glucocorticoid receptor and a 1000-fold higher topical anti-inflammatory potency than cortisol (rat croton oil ear edema assay).

As a measure of systemic activity, budesonide is 40 times more potent than cortisol when administered subcutaneously and 25 times more potent when administered orally in the rat thymus involution assay. The clinical significance of these findings is unknown. The activity of PULMICORT RESPULES is due to the parent drug, budesonide.

In glucocorticoid receptor affinity studies, the 22R form was two times as active as the 22S epimer. In vitro studies indicated that the two forms of budesonide do not interconvert. The precise mechanism of corticosteroid actions on inflammation in asthma is not well known. Inflammation is an important component in the pathogenesis of asthma.

Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic- and non-allergic-mediated inflammation. The anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma.

Studies in asthmatic patients have shown a favorable ratio between topical anti-inflammatory activities and systemic corticosteroid effects over a wide dose range of inhaled budesonide in a variety of formulations and delivery systems including an inhalation-driven, multi-dose dry powder inhaler and the inhalation suspension for nebulization. This is explained by a combination of a relatively high local anti-inflammatory effect, extensive first pass hepatic degradation of orally absorbed drug (85-95%) and the low potency of metabolites (see below).

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics The therapeutic effects of conventional doses of orally inhaled budesonide are largely explained by its direct local action on the respiratory tract. To confirm that systemic absorption is not a significant factor in the clinical efficacy of inhaled budesonide, a clinical study in adult patients with asthma was performed comparing 400 mcg budesonide administered via a pressurized metered dose inhaler with a tube spacer to 1400 mcg of oral budesonide and placebo.

The study demonstrated the efficacy of inhaled budesonide but not orally administered budesonide, even though systemic budesonide exposure was comparable for both treatments, indicating that the inhaled treatment is working locally in the lung. Thus, the therapeutic effect of conventional doses of orally inhaled budesonide are largely explained by its direct action on the respiratory tract.

Improvement in the control of asthma symptoms following inhalation of PULMICORT RESPULES can occur within 2-8 days of beginning treatment, although maximum benefit may not be achieved for 4-6 weeks. Budesonide administered via a dry powder inhaler has been shown in various challenge models (including histamine, methacholine, sodium metabisulfite, and adenosine monophosphate) to decrease bronchial hyperresponsiveness in asthmatic patients.

The clinical relevance of these models is not certain. Pre-treatment with budesonide administered as 1600 mcg daily (800 mcg twice daily) via a dry powder inhaler for 2 weeks reduced the acute (early-phase reaction) and delayed (late-phase reaction) decrease in FEV 1 following inhaled allergen challenge. HPA Axis Effects The effects of PULMICORT RESPULES on the hypothalamic-pituitary-adrenal (HPA) axis were studied in three, 12-week, double-blind, placebo-controlled studies in 293 pediatric patients, 6 months to 8 years of age, with persistent asthma.

For most patients, the ability to increase cortisol production in response to stress, as assessed by the short cosyntropin (ACTH) stimulation test, remained intact with PULMICORT RESPULES treatment at recommended doses. In the subgroup of children age 6 months to 2 years (n=21) receiving a total daily dose of PULMICORT RESPULES equivalent to 0.25 mg (n=5), 0.5 mg (n=5), 1 mg (n=8), or placebo (n=3), the mean change from baseline in ACTH-stimulated cortisol levels showed a decline in peak stimulated cortisol at 12 weeks compared to an increase in the placebo group.

These mean differences were not statistically significant compared to placebo. Another 12-week study in 141 pediatric patients 6 to 12 months of age with mild to moderate asthma or recurrent/persistent wheezing was conducted. All patients were randomized to receive either 0.5 mg or 1 mg of PULMICORT RESPULES or placebo once daily.

A total of 28, 17, and 31 patients in the PULMICORT RESPULES 0.5 mg, 1 mg, and placebo arms respectively, had an evaluation of serum cortisol levels post-ACTH stimulation both at baseline and at the end of the study. The mean change from baseline to Week 12 ACTH-stimulated minus basal plasma cortisol levels did not indicate adrenal suppression in patients treated with PULMICORT RESPULES versus placebo.

However, 7 patients in this study (4 of whom received PULMICORT RESPULES 0.5 mg, 2 of whom received PULMICORT RESPULES 1 mg and 1 of whom received placebo) showed a shift from normal baseline stimulated cortisol level (≥500 nmol/L) to a subnormal level (<500 nmol/L) at Week 12. In 4 of these patients receiving PULMICORT RESPULES, the cortisol values were near the cutoff value of 500 nmol/L.

The effects of PULMICORT RESPULES at doses of 0.5 mg twice daily, and 1 mg and 2 mg twice daily (2 times and 4 times the highest recommended total daily dose, respectively) on 24-hour urinary cortisol excretion were studied in 18 patients between 6 to 15 years of age with persistent asthma in a cross-over study design (4 weeks of treatment per dose level). There was a dose-related decrease in urinary cortisol excretion at 2 and 4 times the recommended daily dose.

The two higher doses of PULMICORT RESPULES (1 and 2 mg twice daily) showed statistically significantly reduced (43-52%) urinary cortisol excretion compared to the run-in period. The highest recommended dose of PULMICORT RESPULES, 1 mg total daily dose, did not show statistically significantly reduced urinary cortisol excretion compared to the run-in period.

PULMICORT RESPULES, like other inhaled corticosteroid products, may impact the HPA axis, especially in susceptible individuals, in younger children, and in patients given high doses for prolonged periods [see Warnings and Precautions (5.5)].

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Excretion/Elimination: Budesonide is primarily cleared by the liver.

Budesonide is excreted in urine and feces in the form of metabolites.

In asthmatic children 4-6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption: In asthmatic children 4-6 years of age, the total absolute bioavailability (i.e., lung + oral) following administration of PULMICORT RESPULES via jet nebulizer was approximately 6% of the labeled dose. In children, a peak plasma concentration of 2.6 nmol/L was obtained approximately 20 minutes after nebulization of a 1 mg dose.

Systemic exposure, as measured by AUC and C max, is similar for young children and adults after inhalation of the same dose of PULMICORT RESPULES. Distribution: In asthmatic children 4-6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults. Budesonide is 85-90% bound to plasma proteins, the degree of binding being constant over the concentration range (1-100 nmol/L) achieved with, and exceeding, recommended doses.

Budesonide showed little or no binding to corticosteroid-binding globulin. Budesonide rapidly equilibrated with red blood cells in a concentration independent manner with a blood/plasma ratio of about 0.8. Metabolism: In vitro studies with human liver homogenates have shown that budesonide is rapidly and extensively metabolized.

Two major metabolites formed via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4) catalyzed biotransformation have been isolated and identified as 16α-hydroxyprednisolone and 6β-hydroxybudesonide. The corticosteroid activity of each of these two metabolites is less than 1% of that of the parent compound. No qualitative difference between the in vitro and in vivo metabolic patterns has been detected.

Negligible metabolic inactivation was observed in human lung and serum preparations. Excretion/Elimination: Budesonide is primarily cleared by the liver. Budesonide is excreted in urine and feces in the form of metabolites. In adults, approximately 60% of an intravenous radiolabeled dose was recovered in the urine. No unchanged budesonide was detected in the urine.

In asthmatic children 4-6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight. Special Populations: No differences in pharmacokinetics due to race, gender, or age have been identified.

Hepatic Insufficiency: Reduced liver function may affect the elimination of corticosteroids. The pharmacokinetics of budesonide were affected by compromised liver function as evidenced by a doubled systemic availability after oral ingestion. The intravenous pharmacokinetics of budesonide were, however, similar in cirrhotic patients and in healthy adults.

Nursing Mothers: The disposition of budesonide when delivered by inhalation from a dry powder inhaler at doses of 200 or 400 mcg twice daily for at least 3 months was studied in eight lactating women with asthma from 1 to 6 months postpartum. Systemic exposure to budesonide in these women appears to be comparable to that in non-lactating women with asthma from other studies.

Breast milk obtained over eight hours post-dose revealed that the maximum concentration of budesonide for the 400 and 800 mcg doses was 0.39 and 0.78 nmol/L, respectively, and occurred within 45 minutes after dosing. The estimated oral daily dose of budesonide from breast milk to the infant is approximately 0.007 and 0.014 mcg/kg/day for the two dose regimens used in this study, which represents approximately 0.3% to 1% of the dose inhaled by the mother.

Budesonide levels in plasma samples obtained from five infants at about 90 minutes after breast-feeding (and about 140 minutes after drug administration to the mother) were below quantifiable levels (<0.02 nmol/L in four infants and <0.04 nmol/L in one infant) [see Use in Specific Populations (8.2)]. Drug-Drug Interactions Inhibitors of cytochrome P450 enzymes Ketoconazole: Ketoconazole, a strong inhibitor of cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4), the main metabolic enzyme for corticosteroids, increased plasma levels of orally ingested budesonide [see Warnings and Precautions (5.12), Drug Interactions (7.1)].

Cimetidine: At recommended doses, cimetidine, a non-specific inhibitor of CYP enzymes, had a slight but clinically insignificant effect on the pharmacokinetics of oral budesonide.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Budesonide 250 mcg/mL, 2 mL Respiratory Solution (Nebule)₱26.55–₱64.00Reference ₱35.00per nebuleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Budesonide
PNF listingDPI: 100 micrograms/dose x 200 doses with appropriate accompanyingdispenser
PNF listingDPI: 200 micrograms/dose x 100 doses and 200 doses with appropriate accompanying dispenser
PNF listingMDI: 200 micrograms/dose x 120 actuations
PNF listingResp. Soln.: (for nebulization) 250 micrograms/mL,
PNF listingResp. Soln.: 2 mL (unit dose)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. PULMICORT RESPULES · AstraZeneca Pharmaceuticals LP [US FDA-approved label, version 23, October 11, 2019]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33cd9834-76df-4f26-3fa2-aab6b9eee8f2
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .